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7RESEARCH ARTICLE Open AccessSynthetic versus natural curcumin: bioequivalence
in an in vitro oral mucositis model
Sonja C Lüer1*, Jeannette Goette2, Rolf Troller3 and Christoph Aebi1,3Abstract
Background: Curcumin (CUR) is a dietary spice and food colorant (E100). Its potent anti-inflammatory activity by
inhibiting the activation of Nuclear Factor-κB is well established.
Methods: The aim of this study was to compare natural purified CUR (nCUR) with synthetically manufactured CUR
(sCUR) with respect to their capacity to inhibit detrimental effects in an in vitro model of oral mucositis. The
hypothesis was to demonstrate bioequivalence of nCUR and sCUR.
Results: The purity of sCUR was HPLC-confirmed. Adherence and invasion assays for bacteria to human pharyngeal
epithelial cells demonstrated equivalence of nCUR and sCUR. Standard assays also demonstrated an identical
inhibitory effect on pro-inflammatory cytokine/chemokine secretion (e.g., interleukin-8, interleukin-6) by Detroit
pharyngeal cells exposed to bacterial stimuli. There was bioequivalence of sCUR and nCUR with respect to their
antibacterial effects against various pharyngeal species.
Conclusion: nCUR and sCUR are equipotent in in vitro assays mimicking aspects of oral mucositis. The advantages
of sCUR include that it is odorless and tasteless, more easily soluble in DMSO, and that it is a single, highly
purified molecule, lacking the batch-to-batch variation of CUR content in nCUR. sCUR is a promising agent for
the development of an oral anti-mucositis agent.
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Curcumin (CUR), a natural compound extracted from the
yellow root plant Curcuma longa (Linn.) [1], is a widely
known spice and yellow colorant (E100) used in food
and drinks worldwide [2]. Since millennia, CUR has also
been highly appreciated as a medical remedy with anti-
inflammatory and antimicrobial properties. Its therapeutic
use in traditional medicines varies from topical application
on wounds to systemic oral application [3]. Modern medi-
cine recently became increasingly interested in the various
biological effects of the active compounds extracted from
the yellow root, mainly CUR and its derivatives. To test
the effects of CUR in various settings in the laboratory,
commercially available extracts from the root are used.
The root itself contains about 3% of CUR (diferuloyl-
methane), several of its derivatives, and oils, resins and
other co-factors from the rhizome. Thus, effects* Correspondence: sonja.lueer@insel.ch
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reproduction in any medium, provided the orattributable to CUR as the active agent remain unclear in
most experiments. Standardization of the effects of CUR
and of curcuminoids remains difficult, since in the major-
ity of studies the exact composition of the CUR powder
used is not specified, and in preparations with a declared
percentage of CUR content the remaining components
are not outlined in detail. Thus, the effects seen could pos-
sibly be attributed in part to the combination of CUR and
curcuminoids as well as to other components of the prep-
aration. Most production processes include purification or
concentration during or after the extraction from the root
to achieve high concentrations of CUR. Even though stan-
dardized and regulated by authorities, there is a possibility
of contamination of nCUR with substances used during
plant growth, from the environment, and from the pro-
duction and purification processes (e.g. fertilizers, heavy
metals, spores).
To compare a synthetically manufactured high purity
curcumin (sCUR) to a standard nCUR, we used our pre-
viously established in vitro mucositis system [4,5] andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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properties of both substances to determine how effective
the > 99% pure sCUR acts in comparison with standard
nCUR. sCUR could possibly serve as a topical agent
against cancer therapy-induced and other forms of oral
mucositis.
Methods
Microorganisms, cell lines and culture conditions
Microorganisms were grown in Brain-Heart Infusion
broth (BHI) at 37°C in a 5% CO2 atmosphere or in air at
150 revolutions per minute (rpm). Clinical isolates in-
cluded Moraxella catarrhalis ATCC 25238 [4], M. catar-
rhalis O35E [6], Streptococcus pneumoniae serotype 6B
[5] and nontypable Haemophilus influenzae [5]. The hu-
man pharyngeal cell line Detroit 562 (ATCC CCL 138)
was maintained in Eagle’s minimal essential medium
(MEM, Invitrogen, Basel, Switzerland) supplemented as
indicated with heat-inactivated fetal calf serum (FCS),
2 mM L-glutamine, 1 mM sodium pyruvate (Sigma, St.
Louis, MO), 1x nonessential amino acids (Sigma), 100
U/ml penicillin, and 100 μg/ml streptomycin at 37°C in
an atmosphere containing 5% CO2.
Reagents
nCUR, purified from Curcuma longa (Turmeric), was
purchased from Sigma (St. Louis, MO) (No. C1386). Ac-
cording to the manufacturer, it contains > 65-70% diferu-
loylmethane (CUR) and greater than 90% curcuminoids
by HPLC. Commercially available sCUR was obtained
from Aptuit Laurus Ltd., Visakhapatnam, India, a Good
Manufacturing Practice (GMP) approved manufacturing
site. The procedure of synthesis is proprietary. The
batches of sCUR used were reported to be greater than
99% pure by high pressure liquid chromatography
(HPLC) and to contain residual amounts of ethyl acet-
ate, methanol, toluene, and n-butanol. sCUR from this
manufacturer fulfils FDA approved GRAS (Generally
Regarded As Safe) safety criteria. We confirmed the pur-
ity of sCUR using our in house HPLC. As indicated by
the manufacturer (purity, 99.6%), we found an overall
purity of 99.7% (98.2% and 1.5% in keto- and enol-form,
respectively). For use in experimental procedures, both
nCUR and sCUR were solubilized in fresh dimethylsulf-
oxide (DMSO) (stock solution, 73.678 mg/ml, i.e.,
200 mM) and added to cell culture or growth media.
Thus, the standard working concentration of 200 μM
CUR contained 0.1% DMSO. Also, negative controls
(phosphate-buffered saline (PBS), MEM, BHI broth)
contained 0.1% DMSO, unless noted otherwise.
Detection of cytotoxicity
Cytotoxicity Detection Kit Plus (LDH)® from Roche
Diagnostics GmbH, Mannheim, Germany was used todetect CUR-induced cytotoxicity to Detroit epithelial
cells after 4 hours of exposure to various concentra-
tions of CUR. Three independent experiments were
performed.
Time-kill experiments of bacteria exposed to CUR
M. catarrhalis, S. pneumoniae and nontypable Hae-
mophilus influenzae were grown in BHI to an OD600 of
0.4 (~5×107 colony forming units (cfu)/ml), aliquoted,
and subsequently grown in medium supplemented with
20, 50, and 100 μM nCUR or sCUR, respectively.
Growth in BHI containing 0.05% DMSO was used as
control. Quantitative cultures were obtained by serial
plating of 100 μl-aliquots at 0, 60, 120, 180 and 240 mi-
nutes, respectively.
Epithelial cell adherence assays
The ability of nCUR or sCUR to inhibit the attachment of
M. catarrhalis to Detroit cells in vitro was measured as
previously described [7]. Briefly, Detroit cells (~2.5×105
per well) grown to a confluent monolayer in 24-well tissue
culture plates were exposed to various concentrations of
nCUR or sCUR (0–200 μM) for 60 minutes in MEM sup-
plemented with 10% FCS, followed by washing three times
in MEM. Bacteria grown overnight were adjusted to a
multiplicity of infection (MOI) of 30. Bacteria were then
added to tissue culture wells in MEM without antibiotics,
centrifuged for 5 min at 1500 rpm, and incubated for
30 minutes at 37°C. Wells were then washed 5 times in
MEM, trypsinized, and the suspensions were cultured
quantitatively to determine the number of adherent bac-
teria. Data were expressed as the proportion of bacteria,
i.e. cfu, of the original inoculum adhering to the epithelial
cells. Each assay was performed in triplicate and at least
three experiments were performed.
Epithelial cell invasion assays
Bacterial invasion was estimated using a conventional
gentamicin protection assay as previously described [8]
with the following modifications. Cells were prepared in
MEM without antibiotics and subsequently exposed to
CUR as described for the adherence assays. After wash-
ing, bacteria were added at MOI 30, centrifuged for
5 min at 1500 rpm and incubated for 3 h at 37°C in 5%
CO2. To determine the number of intracellular bacteria,
the infected monolayer was washed three times in PBS
and treated with gentamicin sulfate (200 μg/ml) for 2 h
at 37°C in order to kill all extracellular bacteria. After
washing, cells were detached from the plastic surface by
treatment with 0.25% trypsin-EDTA, lysed by the
addition of 1% saponin, and serially diluted in PBS for
quantitative bacterial culture. Invasion ratios were calcu-
lated by dividing the number of cfu recovered after gen-
tamicin exposure by the number of cfu inoculated.
Figure 2 Bactericidal effects of nCUR versus sCUR. Comparative
quantitative time-kill analysis of nCUR versus sCUR for M. catarrhalis
strain O35E. Quantitative cultures were obtained at 0, 60, 120, 180,
and 240 minutes. Killing kinetics were similar for both nCUR and
sCUR at all concentrations tested (20, 50, and 100 μM). The negative
control medium consisted of BHI containing 0.05% DMSO.
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Detroit cells stimulated with live whole bacteria
Monolayers of Detroit cells in 24-well plates were pre-
pared as described above and pre-incubated with nCUR
or sCUR at 0 (i.e., MEM with 10% FCS and DMSO only),
100 or 200 μM for 0, 15, 30 or 60 min, respectively. Wells
were then washed to remove CUR and subsequently in-
fected at a MOI of 100. To exclude pro-inflammatory
activation by CUR only, mock infection (MOI 0) after
pre-exposure with 200 μM of CUR was performed as a
negative control. Ten μg/ml of lipopolysaccharide from
Salmonella enteritidis (Sigma) was used as positive
control. After 4 hours, cell culture supernatants were
removed, centrifuged and stored at −80°C before deter-
mination of cytokine/chemokine concentrations. Interleu-
kin (IL)-8 was determined using a commercially available
ELISA kit according to the manufacturer’s protocol (R&D
Systems, Minneapolis, MN). For determination of add-
itional cytokines and chemokines in the same cell super-
natants the Luminex® xMAP® technology was used [5].
Milliplex map kits (Milliplex Corporation) were used for
microsphere-based multiplex immunoassays. Using a
commercially available eight-plex kit, IL-6, IL-8, IL-10,
Monocyte chemoattractant protein 1 (MCP-1), Tumor
Necrosis Factor α (TNF α), Vascular Endothelial Growth
Factor (VEGF), Fibroblast Growth Factor 2 (FGF-2), and
Granulocyte Macrophage-Colony Stimulating Factor
(GM-CSF) were determined according to the manufac-
turer’s instructions. Supernatants from three independent
experiments, each run in duplicates, were tested. Values
below the detection limit were given an arbitrary value
suggested by the manufacturer.
Statistical analysis
Two-way analysis of variance (ANOVA) with Bonferro-
ni’s post-test correction was used (GraphPad Prism 5.02Figure 1 Cytotoxicity of CUR for Detroit 562 cells. Cytotoxicity
assay. Monolayers of Detroit 562 cells were exposed to various
concentrations of nCUR or sCUR, respectively, as indicated. The
proportion of toxicity is indicated as mean + 1 SEM of three consecutive
experiments run in triplicate, i.e., 9 data points per condition were
tested. The positive control was provided by the manufacturer of the kit
and led to complete cell lysis (defined as 100% lysis).statistics package, San Francisco, CA). P values < 0.05
were considered statistically significant.
Results
Characterization of nCUR and sCUR
While nCUR is a yellow powder, which at our standard
working concentration of 200 μM has its characteristicFigure 3 Effect of nCUR versus sCUR on bacterial adherence.
M. catarrhalis adherence assay. After pre-incubation of Detroit cells for
60 minutes with nCUR or sCUR, respectively, at the indicated concentra-
tions, bacteria (M. catarrhalis ATCC 25238) were inoculated onto the
monolayers at a MOI of 30, centrifuged, and incubated for 30 min at
37°C. Non-adherent bacteria were removed and adherent bacteria were
determined by quantitative culture of trypsinized cells. The overall
ANOVA test statistic revealed a p < 0.0001, the between-column values
calculated using Bonferroni’s multiple comparisons test were >0.05 for
nCUR versus sCUR at 100 or 200 μM, respectively. Mean adherence
ratios + 1 SD of three independent experiments, each run in triplicate, are
shown. MEM containing 0.1% DMSO, but no CUR, was used as control.
Figure 4 Effect of nCUR versus sCUR on bacterial invasion.
Determination of invasion of Detroit cells by M. catarrhalis strain
25238 using a gentamicin protection assay. Cells were pre-treated
with 0, 100 or 200 μM of nCUR or sCUR, respectively, for 1 hour.
Following 3 hours of infection, extracellular bacteria were killed by
exposure to gentamicin for 2 hours. Following cell lysis, quantitative
bacterial cultures identified viable intracellular bacteria. The ANOVA
overall p value was 0.112. In-between column p values were > 0.05.
Mean adherence ratios + 1 SEM of three independent experiments,
each run in triplicate, are shown.
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powder, is entirely odorless and tasteless. Maximum
solubility in water, PBS or MEM supplemented each
with 0.1% vol/vol of DMSO was somewhat better for
sCUR at 500 μM. Both nCUR and sCUR demonstrated
minimal and comparable cytotoxicity when LDH was
determined in the supernatant after a 4-hour exposure
of a monolayer of Detroit cells to up to 400 μM CUR
(Figure 1). It is of note that at concentrations exceeding
200 μM nCUR was not entirely in solution. AlthoughFigure 5 Inhibition of IL-8 secretion by nCUR versus sCUR. IL-8 secretio
(green) or sCUR (red) and subsequently infected for 4 hours with live M. ca
CUR, MOI 100). ● (200 μM nCUR, MOI 0) and ■ (200 μM sCUR, MOI 0) are n
difference between nCUR and sCUR for a given concentration.the fluid appeared clear, centrifugation resulted in the
formation of a small pellet.
Bactericidal activity of nCUR versus sCUR
CUR is known to have antibacterial and antifungal activ-
ity, the extent of which is both species- and strain-
dependent [5]. In order to compare nCUR and sCUR we
chose two well characterized strains of M. catarrhalis
for time-kill analyses. While strain ATCC 25238 was
highly susceptible to CUR (data not shown) [5], a con-
centration of 100 μM CUR was required to result in a
bactericidal effect in strain O35E (Figure 2). Importantly,
there was no difference between nCUR and sCUR. S.
pneumoniae serotype 6B and non-typable H. influenzae
were also tested with no difference between nCUR and
sCUR (data not shown).
Inhibition of bacterial adherence and invasion to
epithelial cells
While 100 μM CUR did not significantly inhibit bacterial
adherence to Detroit cells (Figure 3), both 200 μM nCUR
and sCUR demonstrated a statistically significant inhibi-
tory effect. There was, however, no difference between the
two forms of CUR (nCUR, 17.1% vs. sCUR, 19.8%, not
significant). Both values were significantly lower than the
control (49.8%, p < 0.05). The effect of CUR on cellular in-
vasion of bacteria using the gentamicin protection assay
was more difficult to assess. In contrast to previous find-
ings [4], CUR did not significantly inhibit invasion. Al-
though the proportion of invading bacteria was somewhat
lower in cells exposed to 200 μM sCUR, this difference
was not statistically significant (Figure 4).
Inhibition of epithelial cytokine/chemokine release by
CUR
As previously established, IL-8 was used as a representa-
tive of pro-inflammatory cytokines/chemokines [4,5].n by Detroit cells preincubated for 0, 15, 30 or 60 minutes with nCUR
tarrhalis strain 25238 (MOI 100). □ indicates the positive control (0 μM
egative controls. At no time point there is was a statistically significant
Figure 6 Inhibition of release of pro-inflammatory cytokines by
nCUR versus sCUR. Effect of nCUR and sCUR on secretion of GM-
CSF, IL-6, IL-8, MCP-1, VEGF, and TNFα by Detroit cells preincubated
for 0 or 60 minutes with 200 μM nCUR (green) or 200 μM sCUR (red)
and subsequently infected for 4 hours with live M. catarrhalis strain
25238 (MOI 100). □ (black) indicates the positive control (0 μM CUR,
MOI 100). At no time point there is a statistically significant difference
between nCUR and sCUR.
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larly inhibit IL-8 secretion by Detroit cells (no statistical
difference). This effect was seen for both concentrations
of CUR tested. In addition, Luminex technology was
used to assess the same cell supernatants for concentra-
tions of GM-CSF, IL-6, IL-8, IL-10, MCP-1, VEGF, FGF-
2, and TNFα. As expected [5], the release of all cyto-
kines/chemokines with the exception of IL-10 and FGF-
2 (not shown) was fully suppressed by pre-exposure to
nCUR or sCUR for 60 minutes followed by stimulation
of the monolayer with a bacterial MOI of 100 for 4 hours
(Figure 6).
Discussion
As of today, in vitro laboratory work and clinical trials
with CUR (diferuloylmethane) have exclusively used
nCUR purified from the root of Curcuma longa [9]
or chemically synthesized derivatives or nanoparticles
[10,11]. This is a reasonable approach because highly
purified nCUR can be produced in large quantities and
has proved effective in many experimental assays and as
a food additive and colorant (E100) [12]. However, as
elaborated above, purified nCUR is always contaminated
by other chemicals (e.g., demethoxycurcumin, bisdeme-
thoxycurcumin, oils and resins) [12], which may or may
not influence the biological effects attributed to nCUR.
A large number of CUR analogs have thus been synthe-
sized in recent years, and many displayed activities simi-
lar to the mother compound [12,13]. A more recent
approach, fully synthetic manufacturing of diferuloyl-
methane (sCUR), offers the potential to study the effects
of this particular molecule without interference by
contaminants.
In our line of work, i.e., the characterization of CUR
as a potential therapeutic agent against cancer therapy-
induced oral mucositis [4,5], sCUR offers a number of
potential advantages. In contrast to turmeric with its
musky, bitter, and piquant flavor [12], it is entirely odor-
less and tasteless, and therefore suitable as an ingredient
of an orally administered preparation, particularly for
children. Since it appears somewhat more soluble in
DMSO than nCUR, aqueous solutions for oral applica-
tion can be produced with less DMSO (i.e., 0.04% vs.
0.1%, vol/vol). In this context, it is worth mentioning
that CUR has recently also been shown to inhibit adher-
ence to teeth and extracellular matrix of Streptococcus
mutans, the major causative agent of human caries
[14,15]. In the present study we found that antimicrobial
activity of sCUR in standard time-kill analyses was indis-
tinguishable from nCUR [5,16,17] on a weight per vol-
ume basis for 3 major pharyngeal species (Figure 2).
With respect to prevention of mucositis, the key find-
ings of this comparative analysis addressed the anti-
inflammatory properties of the two different CURpreparations and are shown in Figures 3, 4, 5, and 6.
First, both nCUR [4] and sCUR inhibited bacterial ad-
herence to pharyngeal epithelial cells to a similar extent.
Attachment of microorganisms is the first step in initiat-
ing inflammation by avoiding their elimination by the
flow of mucosal secretions. It enhances their ability to
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tachment also allows intimate interaction with cellular
pattern recognition receptors (e.g., Toll-like receptors),
which activate downstream pro-inflammatory cascades
including activation of NF-κB [18,19]. Second, there was
no difference in the invasion ratio of live bacteria ex-
posed to either nCUR or sCUR. However, in contrast to
previous findings [4], we observed no CUR-induced in-
hibition of cellular penetration. Third, both nCUR and
sCUR equally inhibited the secretion of several pro-
inflammatory cytokines (e.g., IL-8, IL-6, MCP-1, GM-
CSF) upon stimulation with live bacteria. This finding
provides indirect evidence that nCUR and sCUR are
equally potent in inhibiting the dissociation of IκB from
NF-κB [20], and thus in down-regulating inflammation.
To our knowledge, this is the first study, which com-
pares sCUR and nCUR in an in vitro model designed to
mimic the pro-inflammatory action of bacteria on hu-
man pharyngeal cells.
Our study has a number of limitations. We used a
simple mucositis model, which may substantially devi-
ate from true in vivo conditions. Also, CUR is reported
to be more stable at pH values below 6.0 [12]. We
used solvents with a buffered pH around 7.0. We con-
sider this justified because human salivary pH typically
varies between 6.5 and 7.2. Our data are thus relevant
for studies mimicking the topical use of CUR in the
oral cavity.Conclusions
The data provided here demonstrate that sCUR and
nCUR are equivalent in a number of in vitro biological
assays, which are designed to mimic bacteria-induced
mucosal surface inflammation. The fact that the con-
centrations used are far below the daily allowances as a
food additive for oral CUR (E100), which amounts to
3 mg/kg/d of nCUR, warrant the claim that sCUR used
at a concentration of 200 μM (e.g., 10 ml of mouth
rinse 4 times daily amounts to a total daily dose of
2.94 mg) is clearly in the range declared safe by the
European Food Safety Authority [21]. An additional ad-
vantage in manufacturing sCUR is the fact that there is
no batch-to-batch variation in the CUR content. Thus,
sCUR appears to be a safe, equipotent and more palat-
able alternative to nCUR, and an excellent candidate
for topical use in clinical oral mucositis trials.
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